A battery-operated TB test designed for low-resource, high-burden settings has earned a nod from the Global Fund’s Expert Review Panel for Diagnostics, the test’s co-developer announced Monday.
Qiagen’s QIAreach QuantiFERON-TB test, co-developed with Australia-based Ellume, offers “ultrasensitive digital detection” of latent tuberculosis infection, according to an Ellume press release. The approval clears the way for the test’s procurement in countries that qualify for Global Fund or…
Japan’s Global Health Innovative Technology (GHIT) Fund will invest $6.6 million in diagnostics, drugs and vaccines development, the nonprofit announced last week.
One award will advance an ongoing Chagas disease drug development project by the Drugs for Neglected Diseases Initiative (DNDI). The five other are new projects: a TB diagnostic, a placental malaria vaccine, a malaria drug, and two separate Chagas drugs (by DNDI/Takeda and DNDI/Daiichi Sankyo).
GHIT Fund’s portfolio…
The TB Alliance has granted Lupin a non-exclusive license to manufacture the nonprofit drug developer’s pretomanid as part of the combination BPaL tuberculosis regimen (with J&J’s bedaquiline and linezolid).
The joint press release issued Monday said the Mumbai-based pharma intends to commercialize pretomanid “in approximately 140 countries and territories, including many of the highest TB burden countries around the world.”
The partners did not disclose deal terms, however…